Mountain View, CA, United States
Mountain View, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Edison Pharmaceuticals | Date: 2016-03-11

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.


Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Aspergers syndrome, childhood disintegrative disorder (CDD), Retts disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.


The present invention relates to methods of treating Lebers hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.


Methods of treating or suppressing mitochondrial diseases, such as Friedreichs ataxia (FRDA), Lebers Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.


A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-to-cotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.


Patent
Edison Pharmaceuticals | Date: 2016-02-10

The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I.


Methods of treating or suppressing mitochondrial diseases, such as Friedreichs ataxia (FRDA), Lebers Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntingtons disease, Parkinsons disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.


Patent
Edison Pharmaceuticals | Date: 2016-01-06

The present invention provides a composition comprising alpha tocotrienol quinone of high purity, wherein the alpha tocotrienol quinone of high purity has a purity of more than 90%, wherein any solvent that can be readily removed from the alpha tocotrienol quinone by evaporation is not considered an impurity, and wherein 2-((6E, 10E)-3R-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione comprises at least 97% of the 2-(3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione material present.


The present invention provides specific 4-(p-quinonyl)-2-hydroxybutanamide derivative compounds, pharmaceutical compositions comprising them, and those compounds and compositions for use methods of treating or suppressing a mitochondrial disorder, modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, and treating a subject suffering from a pervasive developmental disorder selected from the group consisting of Autistic Disorder, Aspergers Disorder, Childhood Disintegrative Disorder (CDD), Retts Disorder, and Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS).


Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Aspergers syndrome, childhood disintegrative disorder (CDD), Retts disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Loading Edison Pharmaceuticals collaborators
Loading Edison Pharmaceuticals collaborators